| Title |
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
|
|---|---|
| Published in |
BMC Neurology, September 2012
|
| DOI | 10.1186/1471-2377-12-95 |
| Pubmed ID | |
| Authors |
Celia Oreja-Guevara, Jaime Ramos-Cejudo, Luiz Stark Aroeira, Beatriz Chamorro, Exuperio Diez-Tejedor |
| Abstract |
The balance between T helper cells Th2- and Th1-related cytokines plays a key role in multiple sclerosis (MS). A shift from a Th1 towards a Th2 cytokine profile could have a beneficial effect on the clinical course of the disease. The objective of this study was to assess Th2/Th1 cytokine profile in relapsing-remitting MS (RRMS) patients receiving an immunosuppressive treatment with natalizumab (NAT), or an immunomodulatory treatment with glatiramer acetate (GA) after one year of treatment. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Egypt | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 175 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Iran, Islamic Republic of | 1 | <1% |
| Spain | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 172 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 29 | 17% |
| Researcher | 24 | 14% |
| Student > Bachelor | 21 | 12% |
| Student > Master | 18 | 10% |
| Other | 14 | 8% |
| Other | 27 | 15% |
| Unknown | 42 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 44 | 25% |
| Agricultural and Biological Sciences | 21 | 12% |
| Biochemistry, Genetics and Molecular Biology | 20 | 11% |
| Neuroscience | 12 | 7% |
| Immunology and Microbiology | 6 | 3% |
| Other | 20 | 11% |
| Unknown | 52 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 April 2024.
All research outputs
#2,186,505
of 25,706,302 outputs
Outputs from BMC Neurology
#200
of 2,723 outputs
Outputs of similar age
#14,301
of 189,607 outputs
Outputs of similar age from BMC Neurology
#4
of 62 outputs
Altmetric has tracked 25,706,302 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,723 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 189,607 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 62 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.